Clinical Trial Supplies Market Share Analysis Report, 2023-2032
The global clinical trial supplies market size was exhibited at USD 42.11 billion in 2022 and is projected to hit around USD 94.34 billion by 2032, growing at a CAGR of 6.5% during the forecast period 2023 to 2032.
Key Pointers:
Clinical Trial Supplies Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 45.65 Billion |
|
Market Size by 2032 |
USD 94.34 Billion |
|
Growth Rate From 2023 to 2032 |
CAGR of 6.5% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Clinical phase, Services, End use, Therapeutic use |
|
Regional Scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key Companies Profiled |
KLIFO A/S; PAREXEL International Corporation; Almac Group Ltd.; Movianto GmbH; Patheon, Inc.; Biocair International Ltd.; PCI Services; Thermo Fischer Scientific, Inc.; Sharp Packaging Services; Catalent Pharma Solutions; Clinigen Group plc; Merck Serono; Chimerix; Piramal Pharma Solutions; UDG Healthcare; EUROFINS; PRA Health Sciences; Liveo Research |
This growth can be attributed to the increasing volume of clinical trial studies coupled with the growing complexity of conducting these trials. The COVID-19 pandemic has created opportunities for local manufacturers. To enhance their foothold in the market, key companies are adopting various plans and policies to gain a higher market share. The clinical trial and pharmaceutical industry is anticipated to witness steady growth, which, in turn, will increase the demand for clinical trial supplies, thereby driving the market growth.
Canada and the U.S. are home to the majority of clinical trials. No language barrier is one of the major factors for the preference of this region for the majority of clinical trials, as the English language is widely spoken in this region. Major CROs and biopharmaceutical companies have their hub in this region, and with advancements in technology, the demand for efficient supplies is increasing and the region is expected to dominate the clinical trial supplies market over the forecast period.
The outbreak of COVID-19 has presented one major challenge, that is, the supply chain vertical of every company is facing limited movement across borders, with national export bans. Thus, companies are adopting various strategies to supply their products to the required destination. The shift toward Direct-to-Patient (DTP) deliveries may overcome the crisis to some extent. The FDA & EMA and regulatory bodies of China, Singapore, & Korea are focusing on DTP deliveries, as an alternative distribution method for investigational product supplies. DTP deliveries have ensured patient adherence and increased participation in clinical trials. For instance, in April 2020, Marken witnessed an increase in onboarded DTP trials in comparison with previous weeks.
Clinical Phase Insights
As of 2022, the phase I segment is anticipated to witness the fastest CAGR of 6.11% during the forecast period. This is attributed to the large influx of phase I trials for COVID-19 treatment and prevention. Based on phases, the market has been segmented into phase I, phase II, phase III, and others. However, the phase III segment dominated the market due to the high requirement for supply chain management in this phase. Even though the phase I clinical trials segment is expected to grow at the fastest rate owing to growing R&D activities in the biotechnology space, the phase III segment is likely to dominate the market during the forecast period.
Phase III clinical trials are more complex than other phases. Although the number of drugs in this phase is comparatively low, the complexity associated with this phase is the highest. The failure rate in this phase is the highest as the sample size and study design require complex dosing at an optimum level. The loss associated with the failure is concerning human and financial, and the majority of failures are due to noncompliance with safety & efficacy standards. Such a scenario may boost the demand for an efficient supply chain and logistics, which, in turn, is expected to positively impact market growth.
Product & Services Insights
In 2022, the supply chain management segment held the largest market share of 47.9%. This scenario exists in most regions worldwide, except in the U.S., wherein the manufacturing segment is also expected to grow at a lucrative rate. The pandemic has widely showcased the scenario of a disrupted supply chain and its impact on the lives of the citizens of a country. This is had propelled the U.S. to become even more self-reliant, eventually laying attention on manufacturing services. The product & service segment in this market includes several processes, from drug development to logistics to distribution. Based on the type of products & services, the market is divided into three major categories, which comprise all the aspects of clinical trial supplies. These include manufacturing, storage & distribution, and supply chain management. Moreover, the manufacturing segment is anticipated to witness the fastest CAGR of 6.2% during the forecast period.
Globalization of clinical trials and an increase in the number of clinical sites are expected to drive the demand for supply chain management systems by life science companies & CROs. The adoption of mobile and supply chain management technology is expected to be the driving factor for segment growth. According to a survey by Sonoco Thermosafe, interactive response systems and Microsoft Office tools are major technologies that are employed by respondents, contributing 25.0% and 24.0%, respectively.
Therapeutic Use Insights
In terms of therapeutic use, oncology is expected to be the fastest & dominant segment, exhibiting a CAGR of 7.3% over the forecast period. This is attributed to the presence of a huge R&D pipeline of oncology drugs. The majority of oncology drugs require temperature-sensitive distribution, which is expected to fuel the demand for cold chain distribution. The segment is majorly categorized into oncology, central nervous system disorders, cardiovascular diseases, infectious diseases, metabolic disorders, and others.
Cardiovascular diseases are known to be the leading cause of death globally. According to the report published by the American Heart Association, in 2019, around 95.1 million people in the U.S. were living with some form of cardiovascular disease, and this disease is the most common cause of mortality in the country compared to cancer & other chronic diseases. It also reported that around 2,300 people in the U.S. die due to cardiovascular disease per day, which is around 1 death every 38 seconds. Thus, such factors are anticipated to propel segment growth during the forecast period. However, introducing a new cardiovascular drug to the market presents many challenges such as stringent regulatory policies for clinical trials and late-stage failures. Supplies are prepared according to changes in the dosage, sites, and packaging design.
End-use Insights
The pharmaceuticals segment held about 43.9% of the total market share in 2022 and is expected to exhibit a CAGR of 6.5% during the forecast period. The clinical trial supplies are used for clinical trials of pharmaceuticals, biologics & medical devices, and other research applications. Procurement, manufacturing, storage, and distribution of clinical trial supplies are done for these segments. Therefore, based on end-use, the clinical trial supplies market is segmented into four types: pharmaceuticals, biologics, medical devices, and others.
There has been a steady decrease in pharmaceutical drugs in the R&D pipeline as it has been substituted by biological drugs, which is expected to have a slightly negative impact on segment growth during the forecast period. The number of pharmaceutical drugs in the top 10 innovative drugs has decreased drastically and is expected to be replaced by biologics. Although pharmaceutical drugs account for the highest number of drugs in the clinical trial segment, the growing number of biological drugs is likely to have an impact on this number. However, the demand for safe, efficacious, and cost-effective medicines is expected to fuel the development of enhanced pharmaceutical drugs, thereby propelling segment growth.
Regional Insights
Asia Pacific is anticipated to grow at the fastest CAGR of 6.11% over the forecast period. North America dominates the market and accounts for the highest number of clinical trials conducted among all regions. Various factors responsible for this growth include the increasing number of healthcare companies conducting clinical trials in the region, supportive government legislation, and the availability of cost-effective products.
Asia Pacific is expected to be one of the fastest-growing regions in the global market. The tremendous growth in clinical research is expected to drive market growth in the region, thereby contributing to market growth. The primary factors driving the growth of clinical research in these regions include the low cost per patient in Asia Pacific countries and the presence of a diverse group of patients that are easy to recruit.
Some of the prominent players in the Clinical Trial Supplies Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Clinical Trial Supplies market.
By Clinical Phase
By Services
By End-use
By Therapeutic Use
By Region
Chapter 1. Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Phase
1.1.2 Product and Service
1.1.3 End Use
1.1.4 Therapeutic Use
1.1.5 Regional Scope
1.1.6 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.3.5.1 Data for Primary Interviews in North America
1.3.5.2 Data for Primary Interviews in Europe
1.3.5.3 Data for Primary Interviews in APAC
1.3.5.4 Data for Primary Interviews in Latin America
1.3.5.5 Data for Primary Interviews in Middle East & Africa
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.2 Volume Price Analysis (Model 2)
1.6.2.1 Approach 2: Volume Price Analysis
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
Chapter 2. Executive Summary
2.1 Market Outlook
Chapter 3. Clinical Trial Supplies Market Variables, Trends, & Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Expansion of Clinical Trial Sites
3.1.1.2 Growing R&D in Biologics and Biosimilars
3.1.1.3 Advancements in Supply Chain Technology
3.1.1.4 Increase in Comparator Sourcing
3.1.2 Market Restraint Analysis
3.1.2.1 Presence of Stringent Regulatory Policies
3.1.2.2 High Possibility of Counterfeiting Drugs
3.1.3 Penetration & Growth Prospect Mapping
3.1.4 SWOT Analysis by PESTEL
3.1.5 Industry Analysis-Porter’s
3.1.6 Clinical Trial Supplies Market: Impact of COVID-19
3.1.6.1 Supply Chain
3.1.6.2 Changing Market Trends
Chapter 4. Clinical Trial Supplies Market: Segment Analysis, By Phase, 2020 - 2032
4.1 Definitions and Scope
4.2 Phase Market Share Analysis
4.3 Segment Dashboard
4.4 Clinical trial supplies Market By Phase
4.4.1 Phase I
4.4.1.1 Phase I Market Estimates and Forecast, 2020 - 2032
4.4.2 Phase II
4.4.2.1 Phase II Market Estimates and Forecast, 2020 - 2032
4.4.3 Phase III
4.4.3.1 Phase III Market Estimates and Forecast, 2020 - 2032
4.4.4 Others
4.4.4.1 Others Market Estimates and Forecast, 2020 - 2032
Chapter 5. Clinical Trial Supplies Market: Segment Analysis, By Services, 2020 - 2032
5.1 Definitions and Scope
5.2 Product and Service Market Share Analysis
5.3 Segment Dashboard
5.4 Clinical Trial Supplies Market by Services
5.4.1 Manufacturing
5.4.1.1 Manufacturing Market Estimates and Forecast, 2020 - 2032
5.4.2 Storage & Distribution
5.4.2.1 Storage & Distribution Market Estimates and Forecast, 2020 - 2032
5.4.2.2 Cold Chain Distribution
5.4.2.3 Non-Cold Chain Distribution
5.4.3 Supply Chain Management
5.4.3.1 Supply Chain Management Market Estimates and Forecast, 2020 - 2032
5.4.4 Comparator Sourcing
5.4.4.1 Comparator Sourcing Market Estimates and Forecast, 2020 - 2032
Chapter 6. Clinical Trial Supplies Market: Segment Analysis, By End Use, 2020 - 2032
6.1 Definitions and Scope
6.2 End-Use Market Share Analysis
6.3 Segment Dashboard
6.4 Clinical Trial Supplies Market by End Use
6.4.1 Pharmaceutical
6.4.1.1 Pharmaceutical Market Estimates and Forecast, 2020 - 2032
6.4.2 Biologics
6.4.2.1 Biologics Market Estimates and Forecast, 2020 - 2032
6.4.3 Medical Devices
6.4.3.1 Medical Device Market Estimates and Forecast, 2020 - 2032
6.4.4 Others
6.4.4.1 Others Market Estimates and Forecast, 2020 - 2032
Chapter 7. Clinical Trial Supplies Market: Segment Analysis, By Therapeutic Use, 2020 - 2032
7.1 Definitions and Scope
7.2 Therapeutic Use Market Share Analysis
7.3 Segment Dashboard
7.4 Clinical Trial Supplies Market by Therapeutic Use
7.4.1 Oncology
7.4.1.1 Oncology Market Estimates and Forecast, 2020 - 2032
7.4.2 Central Nervous System (CNS) Disorders
7.4.2.1 CNS Market Estimates and Forecast, 2020 - 2032
7.4.3 Cardiovascular
7.4.3.1 Cardiovascular Market Estimates and Forecast, 2020 - 2032
7.4.4 Infectious diseases
7.4.4.1 Infectious Diseases Market Estimates and Forecast, 2020 - 2032
7.4.5 Metabolic disorders
7.4.5.1 Metabolic Disorders Market Estimates and Forecast, 2020 - 2032
7.4.6 Dermatology
7.4.6.1 Dermatology Market Estimates and Forecast, 2020 - 2032
7.4.7 Ophthalmology
7.4.7.1 Ophthalmology Market Estimates and Forecast, 2020 - 2032
7.4.8 Respiratory Diseases
7.4.8.1 Respiratory Diseases Market Estimates and Forecast, 2020 - 2032
7.4.9 Others
7.4.9.1 Others Market Estimates and Forecast, 2020 - 2032
Chapter 8. Clinical Trial Supplies Market: Regional Market Analysis, 2020 - 2032
8.1 Regional Market Dashboard
8.2 Definitions and Scope
8.3 Regional Market Share Analysis
8.4 North America
8.4.1 North America Market Estimates and Forecast, 2020 - 2032
8.4.2 U.S.
8.4.2.1 U.S. Market Estimates and Forecast, 2020 - 2032
8.4.3 Canada
8.4.3.1 Canada Market Estimates and Forecast, 2020 - 2032
8.5 Europe
8.5.1 Europe Market Estimates and Forecast, 2020 - 2032
8.5.2 Germany
8.5.2.1 Germany Market Estimates and Forecast, 2020 - 2032
8.5.3 U.K.
8.5.3.1 U.K. Market Estimates and Forecast, 2020 - 2032
8.5.4 France
8.5.4.1 France Market Estimates and Forecast, 2020 - 2032
8.5.5 Italy
8.5.5.1 Italy Market Estimates and Forecast, 2020 - 2032
8.5.6 Spain
8.5.6.1 Spain Market Estimates and Forecast, 2020 - 2032
8.5.7 Netherlands
8.5.7.1 Netherlands Market Estimates and Forecast, 2020 - 2032
8.5.8 Belgium
8.5.8.1 Belgium Market Estimates and Forecast, 2020 - 2032
8.5.9 Switzerland
8.5.9.1 Switzerland Market Estimates and Forecast, 2020 - 2032
8.5.10 Russia
8.5.10.1 Russia Market Estimates and Forecast, 2020 - 2032
8.6 Asia Pacific
8.6.1 Asia Pacific Market Estimates and Forecast, 2020 - 2032
8.6.2 China
8.6.2.1 China Market Estimates and Forecast, 2020 - 2032
8.6.3 Japan
8.6.3.1 Japan Market Estimates and Forecast, 2020 - 2032
8.6.4 India
8.6.4.1 India Market Estimates and Forecast, 2020 - 2032
8.6.5 Australia
8.6.5.1 Australia Market Estimates and Forecast, 2020 - 2032
8.6.6 South Korea
8.6.6.1 South Korea Market Estimates and Forecast, 2020 - 2032
8.6.7 Malaysia
8.6.7.1 Malaysia Market Estimates and Forecast, 2020 - 2032
8.6.8 Indonesia
8.6.8.1 Indonesia Market Estimates and Forecast, 2020 - 2032
8.6.9 Singapore
8.6.9.1 Singapore Market Estimates and Forecast, 2020 - 2032
8.6.10 Philippines
8.6.10.1 Philippines Market Estimates and Forecast, 2020 - 2032
8.7 Latin America
8.7.1 Latin America Market Estimates and Forecast, 2020 - 2032
8.7.2 Brazil
8.7.2.1 Brazil Market Estimates and Forecast, 2020 - 2032
8.7.3 Mexico
8.7.3.1 Mexico Market Estimates and Forecast, 2020 - 2032
8.7.4 Argentina
8.7.4.1 Argentina Market Estimates and Forecast, 2020 - 2032
8.7.5 Colombia
8.7.5.1 Colombia Market Estimates and Forecast, 2020 - 2032
8.8 Middle East and Africa
8.8.1 Middle East & Africa Market Estimates and Forecast, 2020 - 2032
8.8.2 South Africa
8.8.2.1 South Africa Market Estimates and Forecast, 2020 - 2032
8.8.3 Saudi Arabia
8.8.3.1 Saudi Arabia Market Estimates and Forecast, 2020 - 2032
8.8.4 UAE
8.8.4.1 UAE Market Estimates and Forecast, 2020 - 2032
Chapter 9. Clinical Trial Supplies Market - Competitive Analysis
9.1 Company Profiles
9.1.1 Almac Group
9.1.1.1 Company Overview
9.1.1.2 Service Benchmarking
9.1.1.3 Strategic Initiatives
9.1.2 Biocair
9.1.2.1 Company Overview
9.1.2.2 Service Benchmarking
9.1.2.3 Strategic Initiatives
9.1.3 Catalent, Inc.
9.1.3.1 Company Overview
9.1.3.2 Financial Performance
9.1.3.3 Service Benchmarking
9.1.3.4 Strategic Initiatives
9.1.4 KLIFO
9.1.4.1 Company Overview
9.1.4.2 Service Benchmarking
9.1.4.3 Strategic Initiatives
9.1.5 Movianto (Walden Group)
9.1.5.1 Company Overview
9.1.5.2 Service Benchmarking
9.1.5.3 Strategic Initiatives
9.1.6 PCI Pharma Services
9.1.6.1 Company Overview
9.1.6.2 Service Benchmarking
9.1.6.3 Strategic Initiatives
9.1.7 Sharp
9.1.7.1 Company Overview
9.1.7.2 Service Benchmarking
9.1.7.3 Strategic Initiatives
9.1.8 Thermo Fischer Scientific, Inc.
9.1.8.1 Company Overview
9.1.8.2 Financial Performance
9.1.8.3 Service Benchmarking
9.1.8.4 Strategic Initiatives
9.1.9 Marken
9.1.9.1 Company Overview
9.1.9.2 Service Benchmarking
9.1.9.3 Strategic Initiatives
9.1.10 Parexel International Corporation
9.1.10.1 Company Overview
9.1.10.2 Financial Performance
9.1.10.3 Service Benchmarking
9.1.10.4 Strategic Initiatives
9.1.11 Piramal Pharma Solutions
9.1.11.1 Company Overview
9.1.11.2 Financial Performance
9.1.11.3 Service Benchmarking
9.1.11.4 Strategic Initiatives
9.1.12 UDG Healthcare
9.1.12.1 Company Overview
9.1.12.2 Financial Performance
9.1.12.3 Service Benchmarking
9.1.12.4 Strategic Initiatives
9.1.13 EUROFINS
9.1.13.1 Company Overview
9.1.13.2 Financial Performance
9.1.13.3 Service Benchmarking
9.1.13.4 Strategic Initiatives
9.1.14 PRA Health Sciences
9.1.14.1 Company Overview
9.1.14.2 Financial Performance
9.1.14.3 Service Benchmarking
9.1.14.4 Strategic Initiatives
9.1.15 Liveo Research
9.1.15.1 Company Overview
9.1.15.2 Financial Performance
9.1.15.3 Service Benchmarking
9.1.15.4 Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers